PT - JOURNAL ARTICLE AU - Elie, Baptiste AU - Roquebert, Bénédicte AU - Sofonea, Mircea T. AU - Trombert-Paolantoni, Sabine AU - Foulongne, Vincent AU - Guedj, Jérémie AU - Haim-Boukobza, Stpéhanie AU - Alizon, Samuel TI - Variant-specific SARS-CoV-2 within-host kinetics AID - 10.1101/2021.05.26.21257835 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.26.21257835 4099 - http://medrxiv.org/content/early/2021/12/13/2021.05.26.21257835.short 4100 - http://medrxiv.org/content/early/2021/12/13/2021.05.26.21257835.full AB - Since early 2021, SARS-CoV-2 variants of concern (VOCs) have been causing epidemic rebounds in many countries. Their properties are well characterised at the epidemiological level but the potential underlying within-host determinants remain poorly understood. We analyse a longitudinal cohort of 6,944 individuals with 14,304 cycle threshold (Ct) values of qPCR VOC screening tests performed in the general population and hospitals in France between February 6 and August 21, 2021. To convert Ct values into numbers of virus copies, we performed an additional analysis using droplet digital PCR (ddPCR). We find that the number of viral genome copies reaches a higher peak value and has a slower decay rate in infections caused by Alpha variant compared to that caused by historical lineages. Following the evidence that viral genome copies in upper respiratory tract swabs are informative on contagiousness, we show that the kinetics of the Alpha variant translate into significantly higher transmission potentials, especially in older populations. Finally, comparing infections caused by the Alpha and Delta variants, we find no significant difference in the peak viral copy number. These results highlight that some of the differences between variants may be detected in virus load variations.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04653844Funding StatementBE is funded by the Ministere de l'Enseignement Superieur et de la RechercheAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of the CHU of MontpellierI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available online on a gitlab repository https://gitlab.in2p3.fr/ete/sars-cov2_kinetics